Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals, an RNAi therapeutics company, has granted a non-exclusive option for a new target-specific InterfeRx license to Sylentis, a Spanish bio-pharmaceutical company.
Subscribe to our email newsletter
Both the companies will discover, develop and commercialize synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma.
Once Sylentis exercises this option, Alnylam will be entitled to receive upfront and milestone payments, as well as royalties on sales of products covered by the licensing agreement.
The financial details of the deal have not been disclosed.
Alnylam senior vice president and chief business officer Laurence Reid said the deal with Sylentis reflects progress with their InterfeRx program and would create value by leveraging their intellectual property portfolio.